Vienna-II ring applicator for distal parametrial/pelvic wall disease in cervical cancer brachytherapy: An experience from two institutions: Clinical feasibility and outcome

Umesh Mahantshetty, Alina Sturdza*, Pushpa Naga CH, Daniel Berger, Israel Fortin, Laura Motisi, Maximilian P. Schmid, Dheera Aravindakshan, Yogesh Ghadi, Jamema V. Swamidas, Supriya Chopra, Lavanya Gurram, Nicole Nesvacil, Christian Kirisits, Richard Pötter

*Corresponding author for this work
6 Citations (Scopus)

Abstract

Purpose: Recent evidence from EMBRACE shows that around 16% patients with locally advanced cervical cancer (LACC) have residual tumor in distal parametrium (DP) and pelvic wall disease (LPW) after concurrent radio-chemotherapy (CCRT). Adequate target coverage with standard brachytherapy approaches represents a challenge. Therefore, we modified the Vienna I applicator with an add-on cap allowing for additional oblique needles into the DP/LPW (Vienna II). We report here the feasibility and clinical outcomes using Vienna II applicator in LACC patients treated in 2 institutions. Methods and materials: 69 patients with residual disease in DP/LPW after CCRT were accrued. FIGO (2009) stage was 26% IIB, 52% III, 15% IVA, 7% IVB (para-aortic nodes). At diagnosis 91% had disease involving DP/LPW. After CCRT, patients underwent image guided adaptive brachytherapy (IGABT) using Vienna II applicator. IGABT details, acute complications, dose volume parameters and clinical outcome variables were compiled and analyzed. Results: Residual DP/LPW disease at BT was found in 90% patients. Median total number of needles were 7 [3–15], oblique 4 [1–7]. Manageable intraoperative utero-vaginal complications occurred in 8 patients and manageable arterial bleeding in 6 patients during removal. Mean distance between tandem and outer contour of CTVHR was 38 mm and mean CTVHR (±SD) volume was 69 ± 32 cm3. The mean D90 CTVHR was 86 ± 7 Gy (EQD2) and mean (±SD) D2cm 3 (Gy, EQD2) 86 ± 12, 68 ± 7, 68 ± 9 for bladder, rectum and sigmoid respectively. Actuarial LC, PFS, OS at 3/5 years was 76/72%, 56/50%, 62/54% and G3-4 late toxicities (n = 23) were observed in 14 patients (20%). Conclusions: IGABT using Vienna II applicator allows for appropriate target coverage in tumors extending into DP/LPW at the time of BT. Clinical use is feasible and results in good local control, DFS and OS with moderate rate of acute and late ≥G3 toxicity.

Original languageEnglish
JournalRadiotherapy and Oncology
Volume141
Pages (from-to)123-129
Number of pages7
ISSN0167-8140
DOIs
Publication statusPublished - 12.2019

Fingerprint

Dive into the research topics of 'Vienna-II ring applicator for distal parametrial/pelvic wall disease in cervical cancer brachytherapy: An experience from two institutions: Clinical feasibility and outcome'. Together they form a unique fingerprint.

Cite this